HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its exorbitant cost. In the months since, payers are coming around, and more patients have access to this landmark advancement. In June, the Food and Drug Administration approved Yeztugo, an injection of the drug lenacapavir, as a form of HIV PrEP. The…
